US Institute of Medicine proposes biomarker validation framework
This article was originally published in Clinica
Executive Summary
The US FDA should adopt a three-step framework for evaluating and validating biomarkers and convene expert panels to scrutinise those biomarkers that have “regulatory impact”, a US Institute of Medicine (IoM) committee says.